These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1834127)

  • 1. Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation.
    Nicholson RI; Bouzubar N; Walker KJ; McClelland R; Dixon AR; Robertson JF; Ellis IO; Blamey RW
    Eur J Cancer; 1991; 27(7):908-13. PubMed ID: 1834127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer.
    Robertson JF; Bates K; Pearson D; Blamey RW; Nicholson RI
    Br J Cancer; 1992 May; 65(5):727-30. PubMed ID: 1534019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.
    Anderson ED; Forrest AP; Levack PA; Chetty U; Hawkins RA
    Br J Cancer; 1989 Aug; 60(2):223-6. PubMed ID: 2527549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoladex plus tamoxifen versus Zoladex alone in pre- and peri-menopausal metastatic breast cancer.
    Nicholson RI; Walker KJ; McClelland RA; Dixon A; Robertson JF; Blamey RW
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):989-95. PubMed ID: 2149510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
    Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
    Breast Cancer Res Treat; 2011 Aug; 128(3):755-63. PubMed ID: 21625929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy.
    Honma N; Horii R; Iwase T; Saji S; Younes M; Ito Y; Akiyama F
    Breast; 2014 Dec; 23(6):754-62. PubMed ID: 25176593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients.
    Shimizu D; Ishikawa T; Tanabe M; Sasaki T; Ichikawa Y; Chishima T; Endo I
    Breast Cancer; 2014 Sep; 21(5):557-62. PubMed ID: 23184499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.
    Nicholson RI; McClelland RA; Gee JM; Manning DL; Cannon P; Robertson JF; Ellis IO; Blamey RW
    Breast Cancer Res Treat; 1994 Jan; 29(1):117-25. PubMed ID: 7912565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
    Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
    Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G; Beadle G; Thomas S; Mengersen K; Stein S
    Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.
    Robertson JF; Blamey RW
    Eur J Cancer; 2003 May; 39(7):861-9. PubMed ID: 12706354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.
    Dowsett M; Harper-Wynne C; Boeddinghaus I; Salter J; Hills M; Dixon M; Ebbs S; Gui G; Sacks N; Smith I
    Cancer Res; 2001 Dec; 61(23):8452-8. PubMed ID: 11731427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
    Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
    Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients.
    Lien EA; Johannessen DC; Aakvaag A; Lønning PE
    J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):541-3. PubMed ID: 1532904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy.
    Henry JA; Nicholson S; Hennessy C; Lennard TW; May FE; Westley BR
    Br J Cancer; 1990 Jan; 61(1):32-8. PubMed ID: 2153395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.